Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Italy ETF (EWI) vs Moderna, Inc. (MRNA) Price & Performance

Ishares Msci Italy ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Ishares Msci Italy ETF vs Moderna, Inc. — how do they compare? Ishares Msci Italy ETF trades at $63.12, while Moderna, Inc. trades at $63.72 (market cap $24.18B). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

EWIMRNA
Sector
Broad Market / FactorHealth
52-Week High
$63.35$81.80
52-Week Low
$50.31$22.36
Market Cap
$24.18B
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Italy ETF

EWI trades at $63.345, up 0.28% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The stock recently hit a 52-week high, as noted by Zacks Investment Research on June 10, 2026, amid improving industrial data and Italy's recovery narrative. A dividend of $1.17 is scheduled for June 2026, but key financial ratios like P/E and ROE are unavailable from current data.

The outlook is cautiously optimistic due to technical strength and positive sentiment, but risks include European economic volatility from ECB policy shifts and energy price fluctuations. Investors should weigh the bullish trend against potential overbought signals and macroeconomic headwinds.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

About Ishares Msci Italy ETF

EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.

Read more on EWI

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA